Neurofibromin immunoexpression in nerve sheath tumors from nf1 patients

Research output: Contribution to journalArticle

Abstract

The aim of the present study was to assess the differential immunoexpression of neurofibromin in benign and malignant peripheral nerve sheath tumors (PNST) from Neurofibromatosis type l (NF1) patients. Two polyclonal antibodies raised against peptides corresponding to residues 2798-2818 and 509-528 of the NF1 gene product, that specifically recognize the 250 kd NF1 gene product were used. Using enzymatic antigen enhancement these antibodies were applied to formalin-fixed, paraffin-embedded tissue sections. Neurofibromin immunoreactivity was seen in normal dorsal root ganglia, Schwärm cells, keratinocytes, melanocytes, CNS neurons and oligodendrocytes. 38 PNST from 25 NF1 patients were examined. 7/7 malignant PNST immunoexpressed neurofibromin, as detected with both antibodies. 26β1 benign neurofibromas were also positive while immunoreactivity was not detected in 5 benign tumors. Double immunolabelling with S-100 demonstrated neurofibromin within Schwann cells. Immunoabsorption of primary antibodies with corresponding peptides eliminated labelling. Our results negate the concept that malignancy within NF1 tumors is a consequence of neurofibromin deficiency and thus raises additional questions regarding the role of this molecule in the pathogenesis of NF1.

Original languageEnglish (US)
JournalFASEB Journal
Volume10
Issue number3
StatePublished - Dec 1 1996
Externally publishedYes

Fingerprint

Neurofibromin 1
Nerve Sheath Neoplasms
Tumors
nerve tissue
peripheral nerves
neoplasms
Antibodies
Neurilemmoma
antibodies
Genes
peptides
Schwann cells
Neurofibroma
Neoplasms
Peptides
Neurofibromatoses
melanocytes
Melanocytes
Schwann Cells
keratinocytes

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Neurofibromin immunoexpression in nerve sheath tumors from nf1 patients. / Rojiani, Amyn Mohammed; Rojiani, Mumtaz V; Muir, D. F.

In: FASEB Journal, Vol. 10, No. 3, 01.12.1996.

Research output: Contribution to journalArticle

@article{31089b754daf49cc8f2d6e06605bc7d7,
title = "Neurofibromin immunoexpression in nerve sheath tumors from nf1 patients",
abstract = "The aim of the present study was to assess the differential immunoexpression of neurofibromin in benign and malignant peripheral nerve sheath tumors (PNST) from Neurofibromatosis type l (NF1) patients. Two polyclonal antibodies raised against peptides corresponding to residues 2798-2818 and 509-528 of the NF1 gene product, that specifically recognize the 250 kd NF1 gene product were used. Using enzymatic antigen enhancement these antibodies were applied to formalin-fixed, paraffin-embedded tissue sections. Neurofibromin immunoreactivity was seen in normal dorsal root ganglia, Schw{\"a}rm cells, keratinocytes, melanocytes, CNS neurons and oligodendrocytes. 38 PNST from 25 NF1 patients were examined. 7/7 malignant PNST immunoexpressed neurofibromin, as detected with both antibodies. 26β1 benign neurofibromas were also positive while immunoreactivity was not detected in 5 benign tumors. Double immunolabelling with S-100 demonstrated neurofibromin within Schwann cells. Immunoabsorption of primary antibodies with corresponding peptides eliminated labelling. Our results negate the concept that malignancy within NF1 tumors is a consequence of neurofibromin deficiency and thus raises additional questions regarding the role of this molecule in the pathogenesis of NF1.",
author = "Rojiani, {Amyn Mohammed} and Rojiani, {Mumtaz V} and Muir, {D. F.}",
year = "1996",
month = "12",
day = "1",
language = "English (US)",
volume = "10",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "3",

}

TY - JOUR

T1 - Neurofibromin immunoexpression in nerve sheath tumors from nf1 patients

AU - Rojiani, Amyn Mohammed

AU - Rojiani, Mumtaz V

AU - Muir, D. F.

PY - 1996/12/1

Y1 - 1996/12/1

N2 - The aim of the present study was to assess the differential immunoexpression of neurofibromin in benign and malignant peripheral nerve sheath tumors (PNST) from Neurofibromatosis type l (NF1) patients. Two polyclonal antibodies raised against peptides corresponding to residues 2798-2818 and 509-528 of the NF1 gene product, that specifically recognize the 250 kd NF1 gene product were used. Using enzymatic antigen enhancement these antibodies were applied to formalin-fixed, paraffin-embedded tissue sections. Neurofibromin immunoreactivity was seen in normal dorsal root ganglia, Schwärm cells, keratinocytes, melanocytes, CNS neurons and oligodendrocytes. 38 PNST from 25 NF1 patients were examined. 7/7 malignant PNST immunoexpressed neurofibromin, as detected with both antibodies. 26β1 benign neurofibromas were also positive while immunoreactivity was not detected in 5 benign tumors. Double immunolabelling with S-100 demonstrated neurofibromin within Schwann cells. Immunoabsorption of primary antibodies with corresponding peptides eliminated labelling. Our results negate the concept that malignancy within NF1 tumors is a consequence of neurofibromin deficiency and thus raises additional questions regarding the role of this molecule in the pathogenesis of NF1.

AB - The aim of the present study was to assess the differential immunoexpression of neurofibromin in benign and malignant peripheral nerve sheath tumors (PNST) from Neurofibromatosis type l (NF1) patients. Two polyclonal antibodies raised against peptides corresponding to residues 2798-2818 and 509-528 of the NF1 gene product, that specifically recognize the 250 kd NF1 gene product were used. Using enzymatic antigen enhancement these antibodies were applied to formalin-fixed, paraffin-embedded tissue sections. Neurofibromin immunoreactivity was seen in normal dorsal root ganglia, Schwärm cells, keratinocytes, melanocytes, CNS neurons and oligodendrocytes. 38 PNST from 25 NF1 patients were examined. 7/7 malignant PNST immunoexpressed neurofibromin, as detected with both antibodies. 26β1 benign neurofibromas were also positive while immunoreactivity was not detected in 5 benign tumors. Double immunolabelling with S-100 demonstrated neurofibromin within Schwann cells. Immunoabsorption of primary antibodies with corresponding peptides eliminated labelling. Our results negate the concept that malignancy within NF1 tumors is a consequence of neurofibromin deficiency and thus raises additional questions regarding the role of this molecule in the pathogenesis of NF1.

UR - http://www.scopus.com/inward/record.url?scp=33749311037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749311037&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33749311037

VL - 10

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 3

ER -